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A novel CCR2 antagonist inhibits 
atherogenesis in apoE deficient 
mice by achieving high receptor 
occupancy
Ilze Bot  1, Natalia V. Ortiz Zacarías2, Wilhelmus E. A. de Witte3, Henk de Vries2, Peter J. van 
Santbrink1, Daniël van der Velden1, Mara J. Kröner1, Dirk-Jan van der Berg3, Dean Stamos4, 
Elizabeth C. M. de Lange3, Johan Kuiper1, Adriaan P. IJzerman  2 & Laura H. Heitman2
CC Chemokine Receptor 2 (CCR2) and its endogenous ligand CCL2 are involved in a number of 
diseases, including atherosclerosis. Several CCR2 antagonists have been developed as potential 
therapeutic agents, however their in vivo clinical efficacy was limited. In this report, we aimed to 
determine whether 15a, an antagonist with a long residence time on the human CCR2, is effective in 
inhibiting the development of atherosclerosis in a mouse disease model. First, radioligand binding 
assays were performed to determine affinity and binding kinetics of 15a on murine CCR2. To assess 
the in vivo efficacy, western-type diet fed apoE−/− mice were treated daily with 15a or vehicle as 
control. Treatment with 15a reduced the amount of circulating CCR2+ monocytes and the size of the 
atherosclerotic plaques in both the carotid artery and the aortic root. We then showed that the long 
pharmacokinetic half-life of 15a combined with the high drug concentrations ensured prolonged CCR2 
occupancy. These data render 15a a promising compound for drug development and confirms high 
receptor occupancy as a key parameter when targeting chemokine receptors.
The chemokine system comprises more than 20 different chemokine receptors, which belong to the class A or 
rhodopsin-like family of G protein-coupled receptors (GPCRs). Almost 50 chemokine ligands play a critical role 
in the immune system, mediating the migration and differentiation of immune cells during homeostasis and 
inflammation1. Dysregulation of this system can lead to a variety of different pathologies, including inflammatory 
and autoimmune diseases2, 3. For instance, preclinical evidence suggests that CC Chemokine Receptor 2 (CCR2) 
and its high-affinity ligand CCL2 are involved in the pathogenesis of atherosclerosis4–6, neuropathic pain7 and 
multiple sclerosis8. Genetic knockout of CCR2 (CCR2−/−) in the Apolipoprotein E-deficient (apoE−/−) mouse 
model of atherosclerosis resulted in a significant decrease in lesion size compared to apoE−/− controls, which was 
caused by a reduction in monocyte/macrophage recruitment to the atherosclerotic lesion4–6. Similar results have 
been reported in studies with genetic knockout of CCL2 in both the low density lipoprotein receptor-deficient 
(LDLr−/−) and the human Apolipoprotein B transgenic mouse models9, 10. These findings suggest that the CCR2/
CCL2 axis is critically involved in the mobilization and recruitment of monocytes to the early atherosclerotic 
plaque.
The involvement of CCR2 in pathologies such as atherosclerosis has resulted in many efforts to develop bio-
logic and small molecule antagonists targeting this receptor. However, despite inhibitory effects on for example 
monocyte recruitment11, a very limited number of compounds has shown in vivo efficacy in inhibiting atheroscle-
rosis. In this regard, the characterization of the drug-target residence time (RT)—a measure of the ligand-receptor 
complex lifetime—has been proposed as a good predictor of in vivo efficacy and safety12–15. Although the link 
from in vitro kinetics to in vivo outcomes has only been studied in few drug targets, these studies confirm the 
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importance of characterizing the RT of drug candidates16–21. Yet, the impact of RT to prolong the duration of 
effect can only be assessed when considering the whole target biology and pharmacokinetic properties of the drug 
of interest22, 23. Inclusion of RT in early hit-to-lead optimization has also been recently used for the development 
of high-affinity and long-RT CCR2 antagonists24, 25. The combination of structure-affinity and structure-kinetics 
optimization resulted in the discovery of compound 15a (Fig. 1), an orthosteric CCR2 small molecule antagonist 
with high affinity of 2.4 nM and a RT of 714 min for human CCR2 (hCCR2)24. With such a prolonged CCR2 
inhibition, 15a emerges as a potential candidate to evaluate the in vivo effects of long RT.
In this study, we aimed to evaluate the binding kinetics and pharmacokinetics of 15a for murine CCR2 
(mCCR2) and determine whether this CCR2 antagonist is effective in an apoE−/− mouse model of atherosclero-
sis. Using a combination of in vitro radioligand binding assays and in vivo studies, we show that prolonged CCR2 
antagonism with 15a, due to high target occupancy, is linked to a robust and significant inhibition of atherogen-
esis in mice. These results support the need of achieving more than 90% continuous inhibition when developing 
chemokine receptor antagonists26. This study also highlights the importance of in vitro characterization of drug 
candidates in all relevant species for in vivo pre-clinical studies, in order to improve the translational value of 
animal models, and thus to reduce the attrition in drug discovery programs.
Results
Characterization of [3H]INCB3344 and 15a in mouse CCR2 (mCCR2). To determine the binding 
affinity and the kinetic profile of 15a at mCCR2, the radioligand [3H]INCB3344 was first characterized by per-
forming association and dissociation binding assays in membranes of CHO cells transiently expressing mCCR2. 
At 25 °C, binding of [3H]INCB3344 to mCCR2 reached equilibrium around 20 min and was best fit with a one-
phase exponential model that yielded an association (kon) rate of 0.030 nM−1 min−1. Dissociation of the radioli-
gand from mCCR2 was also best fit with a one-phase model that yielded a dissociation rate (koff) of 0.227 min−1 
(Fig. 2 and Table 1). These values resulted in a kinetic dissociation binding constant (KD) of 7.6 nM and a RT of 
4.4 min for this receptor (Table 1).
After the characterization of [3H]INCB3344, we performed displacement experiments at 25 °C with 15a to 
determine its affinity for mCCR2. 15a was able to displace [3H]INCB3344 binding in a concentration-dependent 
way, with a Ki value of 10.6 nM (Fig. 3a). In addition, a [3H]INCB3344 competition association assay was per-
formed in order to determine the kinetic profile of unlabeled 15a. Figure 3b shows a representative competition 
association curve of [3H]INCB3344 to mouse CCR2, in the absence or presence of 30 nM 15a (approximately 
3-fold its Ki value). We used 30 nM 15a as this concentration provided a sufficient window for data analysis. 
Association curves of [3H]INCB3344 in the presence of 15a in mCCR2 resulted in the typical overshoot char-
acteristic for long RT compounds (Fig. 3b) and a KRI > 1.0 (KRI = 1.6). By fitting the curves to the compe-
tition association model of Motulsky and Mahan27, it was possible to determine the kon and koff values of 15a: 
0.007 ± 0.001 nM−1 min−1 and 0.051 ± 0.008 min−1, respectively. These results allowed the calculation of the 
Figure 1. Chemical structure of CCR2 antagonist 15a.
Figure 2. Kinetic characterization of [3H]INCB3344 in murine CCR2. Association and dissociation kinetics 
of 5 nM [3H]INCB3344 binding to membranes of CHO cell membranes transiently expressing murine CCR2 
at 25 °C. Dissociation was initiated by the addition of 10 µM INCB3344. Association and dissociation data were 
fitted using a monophasic exponential association, or exponential decay model, respectively. Graphs shown 
are representative from one experiment performed in duplicate. Data for all association and dissociation 
experiments (n = 3) are presented in Table 1.
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kinetic KD (7.4 ± 1.5 nM), which was comparable to the obtained Ki value, and confirmed a slower dissocia-
tion—and a longer RT of 20 min—compared to [3H]INCB3344 (RT = 4.4 min, Table 1). For comparison, the 
kinetic parameters of 15a and [3H]INCB3344 on human CCR2 (hCCR2) are also shown in Table 1, as previously 
published by Vilums et al.24, 25.
15a reduces circulating CCR2+ monocyte levels. In this study, apoE−/− mice were treated with the 
orthosteric antagonist 15a or vehicle control for four weeks. During the study, body weight, body weight gain 
and plasma total cholesterol levels were not affected by administration of the CCR2 antagonist (Supplementary 
Fig. S1). Liver morphology was similar between the controls and the 15a treated mice, and 15a did not affect 
liver mRNA expression of the toxicity markers ALT, apoH and GC. mRNA levels of AST were even somewhat 
decreased in the 15a treated group (P = 0.02, Supplementary Fig. S2). Interestingly, treatment with 15a resulted in 
increased plasma CCL2 levels, while plasma IL-6 levels remained unaffected (Supplementary Fig. S3). After two 
weeks of treatment, we determined CCR2+ monocyte levels (defined as CD11b+Ly6Glow cells) in blood of control 
and 15a treated mice at two hours after injection by means of flow cytometry. At that time point, we observed a 
significant reduction in the percentage of circulating CCR2+ monocytes in the 15a treated mice (Fig. 4a, controls: 
8.7 ± 1.2%, 15a: 1.8 ± 0.2%, P = 0.0004).
At the time of sacrifice, the total number of monocytes was significantly reduced in the mice treated with 
15a, while total lymphocyte and neutrophil numbers remained unaffected (Supplementary Fig. S4). Flow 
cytometry analysis further confirmed that 15a did not affect the number of neutrophils, CD19+ B cells, CD4+ 
or CD8+ T cells in blood or spleen, nor did we detect any effects of the antagonist on splenic or circulating 
Tregs (data not shown). Of note, these analyses were performed at 18 hour after the last injection of the antag-
onist. At that time-point, we still observed that the number of circulating CCR2+ monocytes was significantly 
reduced in the 15a treated mice compared to controls (Fig. 4b, controls: 14.9 ± 3.2*103 cells/mL versus 15a: 
4.5 ± 1.0*103 cells/mL, P = 0.01). The ratio of patrolling CD11b+Ly6ClowCX3CR1+ monocytes versus inflam-
matory CD11b+Ly6ChighCCR2+ monocytes in blood increased upon treatment with 15a (Fig. 4c), which was not 
only due to a reduction in the number of CCR2+ monocytes, but also caused by a significant 1.5-fold increase in 
the amount of CD11b+Ly6ClowCX3CR1+ monocytes. We did not observe any change in the percentage of circu-
lating CCR5+ monocytes in both the treated and untreated mice, which suggests a selective interaction of 15a 
with CCR2 (Supplementary Fig. S5).
[3H]INCB3344 
(hCCR2b*) 15a (hCCR2b†)
KRI‡ 1.0 (1.0) 1.6 (1.7)
kon (nM−1 min−1) 0.030 ± 0.003 (0.054) 0.007 ± 0.001 (0.008)
koff (min−1) 0.227 ± 0.031 (0.013)
0.051 ± 0.008 
(0.0014)
KD§ (nM) 7.6 ± 1.3 (0.23) 7.4 ± 1.5 (0.175)
RT|| (min) 4.4 ± 0.6 (76) 19.7 ± 3.1 (714)
Table 1. Kinetic characterization of [3H]INCB3344 and 15a in membranes of CHO cells transiently expressing 
murine CCR2 (mCCR2). Values are means ± S.E.M of three separate experiments performed in duplicate. 
*Values of [3H]INCB3344 for hCCR2b were taken from Vilums et al.25. †Values of 15a for hCCR2b were taken 
from Vilums et al.24. ‡Kinetic rate index (KRI) = Bt1/Bt2 (see Materials and Methods). §KD = koff/kon. ||RT = 1/koff.
Figure 3. Characterization of 15a in murine CCR2. (a) Displacement of [3H]INCB3344 binding from CHO 
cell membranes transiently expressing murine CCR2 at 25 °C, upon addition of increasing concentrations 
of compound 15a. (b) Competition association of 5 nM [3H]INCB3344 binding to membranes of CHO cells 
transiently expressing murine CCR2 at 25 °C, in the absence or presence of 30 nM 15a. Data were fitted to 
the competition association model of Motulsky and Mahan27. Graphs shown are representative from one 
experiment performed in duplicate. Data for kinetic experiments (n = 3) are presented in Table 1.
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CCR2 antagonism inhibits atherosclerotic plaque development. Atherosclerotic plaque size 
in the carotid artery at the site of maximal stenosis was reduced from 64.4 ± 11.8*103 µm2 in control mice to 
17.6 ± 4.1*103 µm2 in mice treated with 15a (Fig. 5a, −73%, P = 0.002). Furthermore, as depicted in Fig. 5b,c, 
plaque volume throughout the carotid arteries was reduced from 1.75 ± 0.33*107 µm3 in control mice to 
Figure 4. Effect of 15a treatment on the amount of monocytes. (a) At 2 hours after injection and two weeks 
of treatment, 15a reduced the relative amount of circulating CCR2+ monocytes (defined as CD11b+Ly6Glow 
cells). (b) At 18 hours after the last injection (after 4 weeks of treatment), the number of circulating 
CD11b+Ly6GlowCCR2+ cells was significantly reduced by 15a treatment. (c) The ratio of patrolling monocytes 
and pro-inflammatory monocytes was significantly increased upon treatment with 15a (*P < 0.05, **P < 0.01, 
***P < 0.001). Graphs shown are representative from one experiment with n = 5 per group in panel (a) and 
n = 6 per group in panels (b) and (c).
Figure 5. Inhibition of lesion development in the carotid artery by 15a. (a) The CCR2 antagonist 15a 
significantly reduced atherosclerotic plaque size in the carotid artery at the site of maximal stenosis. (b) 
Similarly, plaque volume, given as plaque size at increasing distance from the collar and (c) as total volume in 
µm3 was significantly reduced by 15a. Micrographs show representative images of the individual groups (100X 
magnification). *P < 0.05, **P < 0.01, ***P < 0.001. Graphs shown are representative from one experiment 
with n = 10 controls versus n = 9 15a-treated mice.
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0.46 ± 0.13*107 µm3 in 15a treated mice (P = 0.003). In addition, relative necrotic area was reduced from 
35.3 ± 8.2% in controls to 7.6 ± 4.5% in the 15a treated mice (P = 0.01).
In the aortic root, average plaque size was significantly reduced by treatment with 15a (Fig. 6a, controls: 
215.9 ± 24.6*103 µm2, 15a: 157.0 ± 15.7*103 µm2, P = 0.005) and also aortic root plaque volume was lower in the 
15a treated mice (Fig. 6b,c, controls: 11.8 ± 1.2*107 µm3, 15a: 7.4 ± 0.7*107 µm3, P = 0.005).
The macrophage content as measured by MOMA2 staining revealed that the macrophage positive area 
of the carotid artery plaques was significantly reduced in the 15a treated mice (Fig. 7a, left panel; controls: 
22.3 ± 4.1*103 µm2, 15a: 6.2 ± 2.5*103 µm2, P = 0.005). Similarly, relative macrophage content (corrected for 
lesion size) was reduced in the 15a treated group (Fig. 7a, right panel; controls: 46 ± 4%, 15a: 25 ± 8%, P = 0.02). 
In the aortic root, macrophage positive area was also significantly lower in the 15a treated mice (Fig. 7b, controls: 
92.0 ± 15.6*103 µm2, 15a: 37.2 ± 8.7*103 µm2, P = 0.008).
Pharmacokinetics-based prediction of target occupancy. To investigate the role of pharmacokinetics 
in the generation of the effective drug response of 15a, we measured the plasma levels of 15a over a 24 hour period 
using a LC-MS method. Following a single intraperitoneal dose of 5 mg/kg, plasma levels of 15a varied from 12 
to 1456 ng/mL 1 h after administration; 2 h after dosing, plasma levels were above 600 ng/mL in all individual 
mice (613 to 1048 ng/mL), which remained relatively constant at 6 h after administration (182 to 1024 ng/mL) 
and fell to 32 to 331 ng/mL at 24 h after administration (Fig. 8a). Pharmacokinetic analysis at this dose revealed a 
relatively slow pharmacokinetic profile (Fig. 8a, elimination half-life = 10.7 hours), with an elimination half-life 
that exceeds by far the determined RT in mCCR2. Using these plasma concentrations, we predicted the target 
occupancy attained by 15a using two different approaches: i) calculation of “equilibrium” target occupancy using 
equation (1) as shown in Materials and Methods, which accounts for both the pharmacokinetics and affinity 
of 15a, and ii) simulation of target occupancy using equations (3–5), which account for the pharmacokinetics 
and binding kinetics of this compound. These calculations demonstrated that the combination of slow pharma-
cokinetics (Fig. 8a) and high drug concentrations relative to affinity leads to a high target occupancy of >90% 
for 24 hours (Fig. 8b, dots). This was confirmed by the simulations of receptor occupancy (Fig. 8b, line), indi-
cating that a simpler calculation method (equation (1)) is sufficient to predict receptor occupancy in this study. 
Comparing the long duration of target occupancy for equilibrium binding with the RT of 15a (of 24 minutes) 
makes clear that RT is not a contributing factor in prolonging target occupancy under these conditions. In this 
Figure 6. Inhibition of lesion development in the aortic root by 15a. (a) Also in the aortic root, 15a inhibited 
atherosclerotic lesion development after 6 weeks of Western type diet. (b) Lesion area in the aortic roots 
presented for each group every 90 μm of the aortic root. (c) Plaque volume was also significantly reduced in the 
15a-treated group. *P < 0.05, **P < 0.01. Graphs shown are representative from one experiment with n = 10 
controls versus n = 9 15a-treated mice.
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regard, equation (2) allowed us to determine the maximal value of koff that could contribute to a prolonged dura-
tion of target occupancy. As previously demonstrated, the level of target saturation can be used to compare the 
plasma elimination with the koff, by multiplying the pharmacokinetic elimination rate with a factor (1-BF), where 
BF represents the percentage of target occupancy divided by 10028. This means that if the target occupancy needs 
to be above 90% for effective treatment, the koff of the drug candidate needs to be ten times lower than the phar-
macokinetic elimination rate.
Discussion and Conclusions
In this study, we investigated the efficacy of the novel CCR2 antagonist 15a—designed to display a long resi-
dence time (RT) on human CCR2 (hCCR2)—in inhibiting the development of atherosclerosis in apoE−/− mice. 
Characterization of the drug-target complex lifetime or RT in early phases of the drug discovery and development 
process might help to improve the prediction of in vivo efficacy and safety12–15. Evidence from retrospective stud-
ies has shown that several marketed drugs exhibit a long RT on their target13, 29, prompting the prospective opti-
mization of both affinity and kinetic properties of compounds for a variety of targets17, 25, 30–32. In this regard, 15a 
was discovered by optimizing a reported lead in the development of MK-0812, a Merck CCR2 antagonist that has 
failed in clinical trials due to lack of efficacy33. Although the RT of MK-0812 in mCCR2 is not known, in hCCR2 
it exhibited an almost 8-fold shorter RT than compound 15a (92 min versus 714 min, respectively)24. Thus, our 
selection of 15a was based on the need of advancing drug candidates with high affinity and favorable binding 
kinetics. In this study, we first determined the kinetic profile of 15a on mouse CCR2 (mCCR2), as the pharmaco-
logical properties of drug candidates, including the kinetic profile, can differ between species orthologues34. This 
renders it necessary to characterize the binding kinetics of lead compounds in all relevant species for preclinical 
testing12. Using [3H]INCB3344 we were able to determine the binding affinity and the kinetic profile of 15a in 
mCCR2. The determination of RT using the competition association model of Motulsky and Mahan27 confirmed 
Figure 7. Macrophage content in carotid artery and aortic root atherosclerotic lesions. (a) Macrophage content 
in the carotid artery lesions as measured by MOMA2 staining was reduced upon treatment with 15a, both in 
total macrophage positive area (left panel) and relatively as percentage of lesion size (right panel). Micrographs 
show representative images of the individual groups (100X magnification). (b) Also in the aortic root, 15a 
significantly reduced the macrophage+ area (left panel). Relative macrophage content did not significantly 
differ between the groups (right panel). Micrographs show representative images of the individual groups 
(40X magnification). *P < 0.05, **P < 0.01. Graphs shown are representative from one experiment with n = 10 
controls versus n = 9 15a-treated mice.
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the longer RT of 15a in comparison with the control [3H]INCB3344, a CCR2 receptor antagonist with similar 
affinity for mCCR2. This is in line with previous studies in hCCR2, where 15a showed a RT of 714 min compared 
with 76 min of [3H]INCB3344 (Table 1)24. However, a clear difference was found between species, as 15a disso-
ciates much faster from mCCR2 than from hCCR2: 15a has a lifetime of less than 30 min on mCCR2, but more 
than 10 hours on hCCR2. This poor translation of kinetic parameters between species represents a clear limitation 
in understanding the effect of RT in in vivo efficacy, adding an extra level of complexity when selecting relevant 
animal models for preclinical studies.
Next we showed that 15a significantly reduced the number of circulating inflammatory CCR2+ monocytes 
and that 15a was very effective in inhibiting atherosclerotic plaque development in both the carotid artery and the 
aortic root of apoE−/− mice. In addition, relative macrophage content in the lesion was reduced in the 15a treated 
mice at both sites of lesion development. CCR2 was previously shown to be predominantly involved in lesion 
initiation4, 6, but seemed less effective in inhibiting lesion progression. For therapeutic application, halting lesion 
progression would be favorable to prevent an existing plaque to progress to an advanced and unstable lesion. In 
this study, 15a almost completely blocked lesion initiation in the carotid artery, as treatment was commenced 
immediately from time of collar placement and thus of lesion development at that site. In the aortic root, early 
atherosclerosis had already developed before treatment was initiated, and treatment was also effective in inhibit-
ing plaque progression in this location. Aiello et al. showed that treatment with the CCR2 antagonist INCB3344 
failed to decrease the size of early and advanced atherosclerotic lesions in apoE−/− mice11, which may be related 
to both the shorter RT of this drug in mCCR2, and the use of an ineffective dose. Although the plasma levels of 
INCB3344 were not investigated in this study, previous data suggest that a single oral dose of 50 mg/kg leads to 
approximately 75% CCR2 inhibition in mice35. In the study by Aiello et al., inflammatory monocyte levels were 
significantly reduced up to 6 hours after oral infusion, which was lost at 9 hours, while we still observed a >60% 
reduction in circulating CCR2+ monocyte numbers at 18 hours after treatment, suggestive of a longer therapeutic 
effect. Interestingly, we also observed an increase in the relative amount of Ly6ClowCX3CR1+ monocytes, which is 
indicative of a more patrolling response36. Similarly as in the study by Aiello et al., we did not observe any effects 
on bone marrow monocyte subpopulations upon treatment (data not shown), suggesting that the reduction 
observed on circulating CCR2+ monocytes is not due to changes in migration of these cells from the bone mar-
row. Further studies should shed more light on the exact mechanisms of depletion of this specific monocyte sub-
set from the circulation, and how this affects the immune system, including effects on other chemokine receptors 
expressed by monocytes. In both studies however, plasma cholesterol levels were not affected, while an increase 
in plasma CCL2, one of the endogenous ligands for CCR2, was observed, which may be explained by the fact that 
clearance of CCL2 is mediated by CCR237. Noteworthy, treatment with 15a resulted in more than 70% reduction 
in carotid artery lesion size, which even exceeds the effects of the CCR2/CCR5/CXCR3 triple antagonist TAK-
779 in inhibiting atherogenesis38, suggesting that inhibition of a single receptor, CCR2, might be sufficient for the 
therapeutic effect in atherosclerosis.
Finally we also investigated the pharmacokinetics of 15a in apoE−/− mice, which allowed us to determine drug 
exposure and predict the target occupancy achieved by 15a after a single dose. For a drug to exert its pharmaco-
logical effect, it must be bound to its target, making target occupancy a requisite for any in vivo effect. Previous 
analysis of clinical trials with CCR1 antagonists led to the conclusion that a receptor occupancy of >90% is 
required for an effective anti-inflammatory response26, 39. Calculation of CCR2 occupancy levels in our study 
Figure 8. Total plasma concentrations, calculated and simulated target occupancy. (a) Observed plasma 
concentrations (dots), linear fit of the data (line) and 95% confidence interval of the linear regression (shaded 
area). (b) Equilibrium occupancy derived from the experimentally observed plasma concentrations (dots) 
and simulated occupancy on basis of the observed binding kinetics and plasma elimination rate (line). Graphs 
shown are representative from one experiment (n = 3 per time point).
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revealed that, after a single dose, 15a was able to block more than 90% of the receptors for over 24 hours. Such 
high level of target engagement can be achieved by slow drug-target dissociation or by target-saturating drug 
concentrations. In our case, the calculated high receptor occupancy is the result of saturating concentrations 
and slow plasma elimination of 15a. For RT to play a key role in increasing the target occupancy, the koff of the 
drug candidate must at least surpass its pharmacokinetic elimination rate22, 23. However, the direct compari-
son of the pharmacokinetic elimination rate and the koff is only informative when the target occupancy is low, 
since it assumes that the declines of the target occupancy and the unbound drug concentration are parallel lines 
on a semi-logarithmic scale. For high levels of target occupancy (i.e. high target saturation), a steep decline of 
unbound drug concentrations is not directly reflected in a steep decline of target occupancy28, as we have pre-
dicted. This reasoning was used to determine the koff value required to prolong target occupancy even further: 
at least a ten-fold difference between the dissociation rate and the plasma elimination rate is required. Although 
the contribution of target saturation is not always recognized in literature19, we provide evidence that the use of 
saturating concentrations can result in the required occupancy levels for an anti-inflammatory effect. However, 
caution must be taken in order to avoid safety risks and toxicity with high doses. These results highlight the need 
of obtaining pharmacokinetic data and using experimental or mathematical approaches to determine receptor 
occupancy in early preclinical studies. In this regard, we have established that a simple “equilibrium” occupancy 
calculation can be sufficient to explain the in vivo efficacy in this study, providing a simple method that can 
be readily used in a range of in vitro and in vivo preclinical studies. This calculation method allows for further 
optimization towards a clinical candidate, for example by developing an oral dosing regimen to improve patient 
compliance.
Although the role of the CCR2:CCL2 axis in the development of atherosclerosis has been recognized in litera-
ture, previous studies with CCR2 small-molecule antagonists failed to successfully inhibit atherosclerosis11, 40. We 
are the first to prove that CCR2 antagonism with a selective small molecule antagonist can result in effective ath-
erogenesis inhibition. The results of our in vivo study provide direct evidence that high receptor occupancy might 
be one of the key factors to improve the translation from in vitro findings into in vivo efficacy in inflammatory 
diseases. In addition, our findings in the in vitro study support the need of characterizing the affinity and kinetic 
profile of drug candidates in multiple species, as a way to improve preclinical and clinical translation of efficacy 
and safety findings12, 41. To conclude, the CCR2 antagonist 15a emerges as a potential candidate for further drug 
development to inhibit atherosclerotic lesion development and progression, and may also be of therapeutic value 
for other diseases involving CCR2.
Materials and Methods
Chemicals and reagents. CCR2 antagonists INCB3344, 15a ((1S,3R)-3-(((R)-5-bromo-2,3-dihydro-1H-
inden-1-yl)amino)-1-isopropylcyclopentyl)(7-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone) 
and the internal standard 15b ((1S,3R)-3-(((S)-5-bromo-2,3-dihydro-1H-inden-1-yl)amino)-1-isopropylcy-
clopentyl)(7-(trifluoromethyl)-3,4-dihydroisoquinolin-2(1H)-yl)methanone) were synthesized in-house as 
described previously24, 42, 43. [3H]INCB3344 (specific activity 32 Ci mmol−1) was custom-labeled by Vitrax 
(Placentia, CA) as a racemic mixture of the two isomers N-(2-(((3S,4S)-1-((1r,4S)-4-(benzo[d][1,3]diox-
ol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide 
and N-(2-(((3R,4R)-1-((1r,4R)-4-(benzo[d][1,3]dioxol-5-yl)-4-hydroxycyclohexyl)-4-ethoxypyrrolidin-3-yl)
amino)-2-oxoethyl)-3-(trifluoromethyl)benzamide. Bovine serum albumin (BSA, fraction V) was purchased 
from Sigma (St. Louis, MO, USA). Bicinchoninic acid (BCA) and BCA protein assay reagent were obtained from 
Pierce Chemical Company (Rockford, IL, USA). Acetonitrile (LC-MS grade), trifluoroacetic acid (TFA) and 
ULC-MS water were from Biosolve (Valkenswaard, the Netherlands); and ethyl acetate from Baker (Deventer, The 
Netherlands). pcDNA3.1+ plasmid containing the murine CCR2 (mCCR2) with an hemagglutinin (HA) epitope 
tag at the N-terminus was cloned in-house. All other chemicals were obtained from standard commercial sources.
Cell culture. Chinese hamster ovary (CHO) cells were cultured at 37 °C and 5% CO2 in Dulbecco’s Modified 
Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) supplemented with 10% (v/v) newborn calf serum, 50 IU/
mL penicillin and 50µg/mL streptomycin. Cells were subcultured twice a week on 10-cm ø plates, at a ratio of 1:20 
to 1:40 using trypsinization.
Transfections. Transient transfection of CHO cells with HA-tagged mouse CCR2 (mCCR2) was performed 
using a polyethyleneimine (PEI) method, as described previously44. Briefly, CHO cells were seeded at 50–60% 
confluence on 15-cm ø plates, transfected with 10 µg of plasmid DNA per plate, and incubated for 48 hrs at 37 °C 
and 5% CO2. Before transfection, the plasmid DNA was diluted in sterile 150 mM NaCl solution and mixed 
with PEI solution (1 mg/mL) to obtain a DNA:PEI mass ratio of 1:6. Finally, the culture medium of the cells was 
refreshed and 1 mL of DNA/PEI mixture was added to the cells, after incubation of the mixture for 20 min at room 
temperature.
Cell membrane preparation. Membranes were prepared as described before44. Briefly, cells were detached 
from 15-cm ø plates by scraping them with 5 ml phosphate-buffered saline (PBS), and the membranes were sepa-
rated from the cytosolic fractions by several centrifugation and homogenization steps. The remaining membrane 
pellet was resuspended in ice-cold Tris buffer (50mM Tris-HCl, pH 7.4) containing 5 mM MgCl2. Membrane pro-
tein concentrations were measured using a bicinchoninic acid (BCA) protein determination with bovine serum 
albumin (BSA) as a standard45.
[3H]INCB3344 Binding assays. Radioligand binding assays were performed in a 100 µL reac-
tion volume containing 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 0.1% 3-[(3-cholamidopropyl)-dim
ethylammonio]-1-propanesulfonic acid (CHAPS), 5 nM [3H]INCB3344 and 50 to 60 µg of membrane protein 
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at 25 °C. Non-specific binding was determined with 10 μM of the cold ligand INCB3344. Displacement assays 
were carried out using 9 concentrations of competing ligand, ranging from 0.1 nM to 100 μM, for 120 min of 
incubation. The kinetic parameters of 15a were also determined at 25 °C using a competition association assay as 
previously described25, 27. For association and competition association experiments, CHO-mCCR2 membranes 
were added to the reaction volume at different time points, in the absence or presence of 30 nM of competing 
ligand. For dissociation experiments, CHO-mCCR2 membranes were first incubated with 5 nM [3H]INCB3344 
for 60 min. Dissociation was initiated by addition of 10 µM of INCB3344 at different time points. For all exper-
iments, incubation was terminated by dilution with ice-cold 50 mM Tris-HCl buffer supplemented with 5 mM 
MgCl2 and 0.05% CHAPS. Separation of bound from free radioligand was performed by rapid filtration over a 
96-well GF/B filter plate using a Perkin Elmer Filtermate-harvester (Perkin Elmer, Groningen, the Netherlands) 
in the case of displacement assays; or over GF/B filters using a Brandel harvester 24 (Brandel, Gaithersburg, MD, 
USA) for kinetic assays. Filter-bound radioactivity was determined by scintillation spectrometry after addition 
of Microscint scintillation cocktail (Perkin-Elmer, Groningen, the Netherlands). The P-E 2450 Microbeta2 plate 
counter (Perkin Elmer, Groningen, The Netherlands) was used for displacement assays, and the TRI Carb 2900 
TR counter (Perkin Elmer, Groningen, The Netherlands) for kinetic assays. In all cases, total radioligand binding 
did not exceed 10% of the amount of radioligand added to prevent ligand depletion.
Animals. This study was performed in compliance with Dutch government guidelines and the Directive 
2010/63/EU of the European Parliament. All animal experiments were approved by the animal welfare committee 
of Leiden University (approval reference number 13213).
Male apoE−/− mice (10–12 weeks old), obtained from the local animal breeding facility (Gorlaeus 
Laboratories, Leiden, The Netherlands), were fed a Western type diet, containing 0.25% cholesterol and 15% 
cocoabutter (SDS, Sussex, UK).
To measure plasma concentrations of 15a over time, Western type diet fed mice were injected with 5 mg/kg 
15a, after which blood samples were taken at fixed time points (1, 2, 6 and 24 hours after injection). Blood samples 
were processed as described below under “Measurement of 15a plasma levels”. The final dose of 5 mg/kg/day was 
based on a pilot study in which two different doses (1.5 and 5 mg/kg/day) were tested using leucocyte migration 
towards the peritoneal cavity as a read-out. Results from this pilot study showed that 1.5 mg/kg per day was not 
effective in inhibiting migration, while 5 mg/kg per day was (data not shown). In addition, the dose of 5 mg/kg 
was also based on a previous study with TAK-77938, in which a dose of 5 mg/kg was used.
To determine the effect of the CCR2 antagonist on atherosclerotic lesion development, mice were fed a 
Western type diet, containing 0.25% cholesterol and 15% cocoabutter (SDS, Sussex, UK) throughout the experi-
ment starting two week before surgery. Carotid artery plaque formation was induced by perivascular collar place-
ment as described previously46 and from the time of surgery, the mice received daily intraperitoneal injections 
containing 15a (5 mg/kg/day) or vehicle control (n = 9–10 per group). During the experiment, total body weight 
and weight gain were measured. Serum total cholesterol levels were determined using an enzymatic colorimet-
ric assay according to manufacturer’s protocol (Roche Diagnostics). Precipath (standardized serum; Boehringer 
Mannheim, Germany) was used as an internal standard. Plasma cytokine levels were measured by ELISA accord-
ing to manufacturer’s protocol (BD Biosciences). Blood was collected weekly via tail cut. Total cell count and 
cellular differentiation patterns in blood were analyzed using an automated XT-2000iV veterinary hematology 
analyzer (Sysmex Europe GMBH, Norderstedt, Germany). After erythrocyte lysis, blood leukocyte suspensions 
were stained for surface markers, after which their expression was determined by FACS analysis (FACS Canto, BD 
Biosciences). After 4 weeks of lesion development, the animals were anaesthetized and blood was collected. After 
in situ perfusion through the left cardiac chamber, the carotid arteries and hearts were harvested.
Measurement of 15a plasma levels. Blood plasma from mice was analyzed by LC-MS to determine 15a 
plasma levels. 20 μL of internal standard (compound 15b, a diastereomer of 15a24) and 20 μL of solvent C (20% 
(v/v) Acetonitrile and 0.1% (v/v) TFA in LC-MS water) were first mixed with 20 µL of plasma. A calibration 
curve from 2 to 200 ng/ml of 15a was prepared using solvent C. Calibration samples were prepared as normal 
samples using blanc plasma and calibration solution instead of solvent C. Aliquots of 40 µL of 1% TFA were added 
to the samples and mixed well. After addition of 900 µL of ethyl acetate, mixing was performed for 5 minutes 
at a titramax plate shaker (Heidolph, Swabach, Germany). Samples were then centrifuged at 15,000 × g dur-
ing 10 minutes and 800 µL of the supernatant was evaporated in a vacuum centrifuge (Labconco, Kansas City, 
Missouri). The sample was reconstituted by mixing with 10 µL of acetonitrile, followed by addition of 40 µL sol-
vent C. After a second centrifugation at 15,000 × g for 10 minutes, 35 µL of supernatant were transferred to LC 
vials and inserted into the LC-MS system consisting of a Nexera X2 UHPLC system with two UHPLC pumps 
(Shimadzu, ’s Hertogenbosch, The Netherlands) connected to a TSQ Quantum Ultra (Thermo Fisher Scientific, 
Breda, The Netherlands). Separation of 15a was accomplished in a Gemini 3 µm C18 reversed phase HPLC col-
umn (50 × 4.6 mm) (Phenomenex, Amstelveen, The Netherlands) using an injection volume of 10 µL and a flow 
rate of 0.6 ml/min at 40 °C. After elution of 15a with a 9:11 (v/v) ratio of acetonitrile in water with 0.1% TFA, the 
column was flushed with a gradient up to 90% acetonitrile with 0.1% TFA. The column was re-equilibrated with 
a 9:11 (v/v) ratio of acetonitrile in water with 0.1% TFA before the next injection. Samples were analyzed by mass 
spectrometry using Electro Spray Ionization at a voltage of 3000 V. 15a and the internal standard 15b showed the 
same fragmentation pattern and were quantified by monitoring the transition of 549.17 to 202.08 (m/z). The col-
lision energy used was 26 V at a skimmer offset of 16 V, the scan peak width was 0.5 m/z, while the scan time was 
0.3 seconds. Sheath gas and auxiliary gas pressure (Nitrogen) were set to 60 and 5 respectively (arbitrary units), 
and the collision gas Argon was set at 1.0 atm.
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Histology and morphometry. Carotid artery cryosections of 5 µm thick were prepared, which were 
stained with hematoxylin-eosin to determine plaque size and necrotic core size. Morphometric analysis was per-
formed on sections throughout the atherosclerotic lesion (100 µm apart) and at the site of maximal stenosis using 
Leica Qwin image analysis software. The relative necrotic area was defined as the a-cellular, debris-rich plaque 
area as percentage of total plaque area, and also quantified using Leica QWin software.
The hearts were dissected just below the atria and sectioned perpendicular to the axis of the aorta, start-
ing within the heart and working in the direction of the aortic arch. Once the aortic root was identified by the 
appearance of aortic valve leaflets, 10 µm sections were collected. Mean lesion area (in µm2) of the aortic root was 
calculated from six Oil-Red-O stained sections in distal direction starting at the point where all three aortic valve 
leaflets first appeared.
Macrophage content of the lesions in carotid arteries and aortic roots was stained using a rat monoclonal 
MOMA2 antibody (1:1000, Serotec, Kidlington, Oxford, UK). Macrophage positive areas were analyzed using 
computer-assisted colour-gated analysis, and related to the total intimal surface area (Leica QWin). Liver cryosec-
tions of 10 µm thick were prepared and subsequently stained with hematoxylin-eosin to analyze liver morphology, 
which was assessed using a Leica DMRE microscope (Leica Ltd., Cambridge, England).
RNA isolation and gene expression analysis. Total RNA was extracted from homogenized liver tis-
sue with the guanidium thiocyanate-phenol-bromochloropropane extraction method38. RNA concentration, 
purity and integrity were examined by nanodrop (Nanodrop® Technologies). RNA was reverse transcribed by 
M-MuLV reverse transcriptase (RevertAid, MBI Fermentas, Landsmeer, The Netherlands) and used for quanti-
tative analysis of the mouse genes ALT, AST, apoH and GC with an ABI PRISM 7700 Taqman apparatus (Applied 
Biosystems). For qPCR primer pairs refer to Supplementary Table S1.
Data analysis. All radioligand binding assays were analyzed using Prism 6.0 (GraphPad software, San Diego, 
CA, USA). All data shown represent means ± SEM of at least three independent experiments performed in dupli-
cate. Ki values were calculated from IC50 values obtained by non-linear regression analysis of the displacement 
assays and by using the Cheng-Prusoff equation47. Dissociation rate constants koff were determined by fitting the 
dissociation data using an exponential decay model. Association rate constants kon were obtained by converting 
the apparent association rate constants kobs according to the equation kon = (kobs − koff)/[L], in which L is the radi-
oligand concentration used for the experiments, kobs is the constant rate determined using exponential associa-
tion analysis and koff represents the mean koff value obtained independently in the dissociation experiments. The 
kinetic profile of compound 15a was determined by calculation of its kinetic rate index (KRI) value48. The KRI 
values were calculated according to the equation KRI = Bt1/Bt2, in which Bt represents the specific radioligand 
binding measured at t1 = 15 min and t2 = 210 min. In addition, the association and dissociation rates of 15a were 
obtained by nonlinear regression analysis of the competition association data using the equations described by 
Motulsky and Mahan27. The association and dissociation rates obtained with this model were used to calculate 
the kinetic KD, according to the equation KD = koff/kon. In addition, the RT was calculated by obtaining the recip-
rocal of the koff. Data obtained from in vivo experiments are expressed as mean ± SEM. An unpaired two-tailed 
Student’s t-test was used to compare individual groups. Non-Gaussian distributed data were analyzed using a 
two-tailed Mann-Whitney U test. A level of P < 0.05 was considered significant.
Pharmacokinetics-based prediction of target occupancy. The equilibrium target occupancy was 
calculated by assuming that binding was fast and the drug-target residence time did not prolong the target occu-
pancy. The target occupancy was calculated for each measurement of the drug concentration, according to equa-









In addition, a simple mathematical model was used to simulate target occupancy for the observed in vivo 
pharmacokinetics and in vitro binding kinetics according to the equations in the next section (equations (3–5)).
To determine the maximal value of koff that would prolong the receptor occupancy even further, we used 
equation (2)28, in which BF represents the percentage of target occupancy divided by 100 and t1/2el represents the 
plasma elimination half-life (0.693/kel). In this case we set BF to 0.90, as 90% represents the minimum value of 
target occupancy to achieve efficacy. To obtain the elimination rate constant of compound 15a, a linear regression 
analysis of the natural logarithm of the concentrations versus time was performed, and the slope coefficient was 
used as the elimination rate constant kel.
< . ⋅ −k BF t0 693 (1 )/ (2)off el1/2
Differential equations for the simulations of target occupancy. The concentrations of unbound 
drug in the blood [C] and target-bound drug [LR] were modeled according to equations (3–5). In these equa-
tions, kel is the first-order elimination rate constant, kon is the second-order association rate constant, koff is the 
first-order dissociation rate constant, [Rfree] is the concentration of unbound receptor and [Rtot] is the concentra-
tion of bound plus unbound receptor, which is assumed to be constant.
= − ⋅ − ⋅ ⋅ + ⋅
d C
dt
k C k C R k LR[ ] [ ] [ ] [ ] [ ] (3)el on free off
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= −R R LR[ ] [ ] [ ] (4)free tot
The concentration of the target-bound drug is calculated according to equation (5):
= ⋅ ⋅ − ⋅
d LR
dt
k C R k LR[ ] [ ] [ ] [ ] (5)on free off
Parameter values: for the simulations in Fig. 8b, kel was set to 0.0647 hr−1, based on the slope of the linear 
regression of the pharmacokinetic data (Fig. 8a). On basis of in-house measurements, koff was set to 3.06 hr−1 
(corresponding to 0.051 min−1, as shown in Table 1) and the KD was set to 10 nM, which corresponds to the Ki 
value of 15a determined in [3H]INCB3344 displacement assays. The Ki value was used instead of the KD (from 
Table 1) as this represents a more conservative choice with regard to target saturation. The receptor concentration 
was set to an arbitrarily low number of 1 pM.
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